ADXN Key Statistics, Chart & Performance
The current stock price of ADXN is 8.05 USD. In the past month the price decreased by -14.36%. In the past year, price decreased by -7.58%.
ADXN Latest News, Press Relases and Analysis
ADXN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.37 | 943.10B | ||
| JNJ | JOHNSON & JOHNSON | 19.42 | 485.76B | ||
| MRK | MERCK & CO. INC. | 11.23 | 245.55B | ||
| PFE | PFIZER INC | 8.05 | 146.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.88 | 105.19B | ||
| ZTS | ZOETIS INC | 18.64 | 52.07B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.41 | 22.32B | ||
| VTRS | VIATRIS INC | 4.76 | 12.77B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.59 | 10.78B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.3 | 8.73B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.44B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About ADXN
Company Profile
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 2 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Company Info
ADDEX THERAPEUTICS LTD
Chemin des Mines, 9
Plan-les-Ouates GENEVE CH-1202 CH
CEO: Tim Dyer
Employees: 2
Phone: 41228841555
ADDEX THERAPEUTICS LTD / ADXN FAQ
What does ADXN do?
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 2 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Can you provide the latest stock price for ADDEX THERAPEUTICS LTD?
The current stock price of ADXN is 8.05 USD. The price increased by 3.6% in the last trading session.
Does ADXN stock pay dividends?
ADXN does not pay a dividend.
How is the ChartMill rating for ADDEX THERAPEUTICS LTD?
ADXN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is ADXN stock listed?
ADXN stock is listed on the Nasdaq exchange.
Would investing in ADDEX THERAPEUTICS LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADXN.
ADXN Technical Analysis
ADXN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ADXN. ADXN may be in some trouble as it scores bad on both profitability and health.
ADXN Financial Highlights
Over the last trailing twelve months ADXN reported a non-GAAP Earnings per Share(EPS) of -8.54. The EPS decreased by -210.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.76% | ||
| ROE | -95.67% | ||
| Debt/Equity | 0 |
ADXN Forecast & Estimates
For the next year, analysts expect an EPS growth of -1500% and a revenue growth -21.42% for ADXN